Literature DB >> 24676694

Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial.

Korhan Kahraman1, Yavuz Emre Sükür, Cem Somer Atabekoğlu, Can Ateş, Salih Taşkın, Serife Esra Cetinkaya, Harun Egemen Tolunay, Batuhan Ozmen, Murat Sönmezer, Bülent Berker.   

Abstract

PURPOSE: To compare the effects of combined oral contraceptives (OCs) containing cyproterone acetate and drospirenone in the treatment of polycystic ovary syndrome (PCOS).
METHODS: Fifty-two patients with PCOS were randomized in two groups: group A (n = 26) received 0.035 mg ethinyl estradiol + 2 mg cyproterone acetate and group B (n = 26) received 0.03 mg ethinyl estradiol + 3 mg drospirenone-containing OCs for 12 months. Baseline clinical features including body mass index, waist to hip ratio (WHR), and modified Ferriman-Gallwey (mFG) score were noted. Baseline biochemical parameters included androgen profile, carbohydrate metabolism, lipid profile, and oxidative stress. The percentages of changes for all parameters were compared.
RESULTS: The groups were comparable regarding the baseline characteristics. WHR decreased significantly from baseline (-4 % [-31 to 35]) in group B when compared to group A (0 % [-11 to 14]) (P = 0.033). The total mFG score decreased significantly from baseline (-35 % [-71 to 10]) in group A when compared to group B (-18 % [-72 to 30]) (P = 0.035). Changes in androgen hormone profile were comparable except DHEA-SO4 (-32 % [-53 to 15] in group B vs. -10 % [-49 to 63] in group A; P = 0.046). The effects of the drugs were similar regarding carbohydrate metabolism, lipid profile, and oxidative stress parameters.
CONCLUSIONS: Cyproterone acetate containing OCs seem to be more effective to treat clinical hirsutism in patients with PCOS after 12 months of treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24676694     DOI: 10.1007/s00404-014-3217-5

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  10 in total

1.  Effect of serotonin modulating pharmacotherapies on body mass index and dysglycaemia among children and adolescents: a systematic review and network meta-analysis protocol.

Authors:  Reem A Al Khalifah; Nicole E De Long; Ivan D Florez; Lawrence Mbuagbaw; Katherine M Morrison
Journal:  BMJ Open       Date:  2016-03-16       Impact factor: 2.692

Review 2.  Endocrine evaluation of hirsutism.

Authors:  John Mihailidis; Racha Dermesropian; Pamela Taxel; Pooja Luthra; Jane M Grant-Kels
Journal:  Int J Womens Dermatol       Date:  2015-06-04

Review 3.  Endocrine evaluation of hirsutism.

Authors:  John Mihailidis; Racha Dermesropian; Pamela Taxel; Pooja Luthra; Jane M Grant-Kels
Journal:  Int J Womens Dermatol       Date:  2017-02-16

4.  Effects of oral contraceptives on metabolic parameters in adult premenopausal women: a meta-analysis.

Authors:  Lina S Silva-Bermudez; Freddy J K Toloza; Maria C Perez-Matos; Russell J de Souza; Laura Banfield; Andrea Vargas-Villanueva; Carlos O Mendivil
Journal:  Endocr Connect       Date:  2020-10       Impact factor: 3.335

Review 5.  Hirsutism, Normal Androgens and Diagnosis of PCOS.

Authors:  Poli Mara Spritzer; Lucas Bandeira Marchesan; Betânia Rodrigues Santos; Tayane Muniz Fighera
Journal:  Diagnostics (Basel)       Date:  2022-08-09

6.  Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial.

Authors:  Qiu-Yi Wang; Yong Song; Wei Huang; Li Xiao; Qiu-Shi Wang; Gui-Mei Feng
Journal:  Chin Med J (Engl)       Date:  2016-04-20       Impact factor: 2.628

Review 7.  Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome.

Authors:  Sebastião Freitas de Medeiros
Journal:  Reprod Biol Endocrinol       Date:  2017-12-08       Impact factor: 5.211

Review 8.  Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis.

Authors:  Mina Amiri; Fahimeh Ramezani Tehrani; Fatemeh Nahidi; Ali Kabir; Fereidoun Azizi
Journal:  JMIR Res Protoc       Date:  2018-04-25

9.  Comparing the Effects of Oral Contraceptives Containing Levonorgestrel With Products Containing Antiandrogenic Progestins on Clinical, Hormonal, and Metabolic Parameters and Quality of Life in Women With Polycystic Ovary Syndrome: Crossover Randomized Controlled Trial Protocol.

Authors:  Mina Amiri; Fatemeh Nahidi; Davood Khalili; Razieh Bidhendi-Yarandi; Fahimeh Ramezani Tehrani
Journal:  JMIR Res Protoc       Date:  2017-09-29

10.  Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone).

Authors:  A Podfigurna; B Meczekalski; F Petraglia; S Luisi
Journal:  J Endocrinol Invest       Date:  2019-10-25       Impact factor: 5.467

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.